Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM
Gilead Sciences shares rose 3.65% to $135.93 after Phase 3 trial results showed Trodelvy plus Keytruda cut the risk of breast cancer progression or death by 35% versus Keytruda and chemotherapy. The company has submitted regulatory filings in the U.S. and Europe. CEO Daniel O’Day plans to sell up to $15.6 million in shares. Investors await Gilead’s earnings report on Feb. 10.